Weight-Loss Drugs Production Expands in Pennsylvania

Weight-loss drugs production expands as Eli Lilly invests $3.5B in a major Lehigh Valley plant, boosting Pennsylvania’s life sciences sector.

February 4, 2026

Nina Dale

Eli Lilly invests $3.5B in a weight-loss drugs manufacturing plant in Lehigh Valley, Pennsylvania.
The project will create 850 jobs and is supported by $100M in state incentives.
The new facility, set to open in 2031, will produce next-generation weight-loss drugs and devices.
This is Lilly’s fourth new US manufacturing site since February 2025, part of a larger $50B domestic expansion.

Key Takeaways

Major Manufacturing Commitment

Eli Lilly will construct a $3.5B plant in Lehigh County, Pennsylvania, dedicated to the production of injectable weight-loss drugs and medical devices, reports the Manufacturing Dive. This marks the largest investment by a life sciences firm in the state, with operations expected to begin in 2031.

The company secured $100M in support from Pennsylvania, including $50M in tax credits and $50M for expansion and job creation. The facility will be located in Fogelsville, an unincorporated community in Lehigh Valley, and will bring 850 new jobs to the region.

Advanced Weight-Loss Drugs Pipeline

The Lehigh Valley plant will focus on manufacturing next-generation weight-loss drugs such as retatrutide, which recently completed late-stage clinical trials with promising results. Retatrutide is designed to treat obesity and type-2 diabetes, showing significant weight reduction and health improvements in participants. Regulatory approval for the drug is pending, with further trials expected this year.

Alongside medicine production, the plant will manufacture related injection devices. Pennsylvania is supplementing the effort with up to $5M for workforce development at local educational institutions to ensure the new roles are filled by qualified candidates.

US Expansion Strategy

The Lehigh Valley facility marks Lilly’s fourth major US site announced since early 2025. It is part of over $50B in planned domestic investments. Lilly also committed to building sites in Virginia, Texas, and Alabama. One of its largest sites will be a $6.5B pharma campus in Houston, focused on expanding cancer treatment and weight-loss drug capacity. These locations will focus on cancer treatments, oral weight-loss drugs, and other therapies.

The new plants will use advanced technologies like AI, integrated monitoring, and data analytics. These tools will improve manufacturing efficiency and reliability across the network.

Lilly’s expansion aligns with growing momentum to reshore pharmaceutical production amid shifting US policy. Other global drugmakers are also making large-scale US investments. The Lehigh Valley site plays a key role in Lilly’s effort to meet demand for weight-loss drugs and boost Pennsylvania’s economy.